Kailera director reports 170,194-share stock option
Kailera Therapeutics director Frank Clyburn reports holding a stock option covering 170,194 shares of common stock at an exercise price of $7.24 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Kailera Therapeutics director Frank Clyburn reports holding a stock option covering 170,194 shares of common stock at an exercise price of $7.24 per share. The option expires on November 5, 2035 and vests 25% on October 31, 2026, then in 36 substantially equal monthly installments.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Clyburn Frank
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 170,194 contracts (Direct)
Footnotes (1)
- F1. The options vest and become exercisable as to 25% of the total shares on October 31, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Underlying option shares: 170,194 shares
Exercise price: $7.24 per share
Option expiration date: November 5, 2035
+2 more
5 metrics
Underlying option shares
170,194 shares
Underlying common stock for reported stock option holding
Exercise price
$7.24 per share
Exercise price of stock option on Kailera common stock
Option expiration date
November 5, 2035
Expiration date of the reported stock option
Initial vesting date
October 31, 2026
25% of option shares vest on this date
Remaining vesting schedule
36 monthly installments
Balance of option vests in 36 substantially equal installments
Key Terms
Stock Option (right to buy), underlying security, exercise price, vest and become exercisable, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock"
exercise price financial
"conversion_or_exercise_price: 7.2400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The options vest and become exercisable as to 25% of the total shares"
substantially equal monthly installments financial
"and thereafter in 36 substantially equal monthly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position does Frank Clyburn report at Kailera Therapeutics (KLRA)?
Frank Clyburn reports holding a stock option linked to 170,194 shares of Kailera Therapeutics common stock. This derivative position reflects potential future ownership if exercised, rather than current common share holdings, and is reported as a direct ownership position on the Form 3.
What is the exercise price of Frank Clyburn’s Kailera Therapeutics (KLRA) stock option?
The stock option reported by Frank Clyburn has an exercise price of $7.24 per share. This means he can purchase up to 170,194 Kailera Therapeutics common shares at $7.24 each if and when the option is vested and exercised.
When do Frank Clyburn’s Kailera Therapeutics (KLRA) options start vesting?
The options begin vesting on October 31, 2026, when 25% of the total shares become exercisable. The remaining portion then vests in 36 substantially equal monthly installments, subject to his continued service on each vesting date with Kailera Therapeutics.
When do Frank Clyburn’s Kailera Therapeutics (KLRA) stock options expire?
The reported stock option expires on November 5, 2035. After this expiration date, any unexercised portion of the 170,194 underlying Kailera Therapeutics common shares would no longer be available to exercise at the $7.24 per share price.
Is Frank Clyburn’s Kailera Therapeutics (KLRA) option holding direct or indirect?
The Form 3 shows Frank Clyburn’s stock option holding as direct ownership. This means the option position tied to 170,194 underlying Kailera Therapeutics common shares is held in his own name rather than through a separate entity or intermediary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates